Mu Wang

Dr. Mu Wang

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
LWLiwen Wang
Liwen Wang
PZPanpan Zhang
Panpan Zhang
MWMu Wang
Mu Wang
RFRuie Feng
Ruie Feng
YLYamin Lai
Yamin Lai
WZWen Zhang
Wen Zhang
The aim of this study was to assess the outcomes of remission induction in patients with IgG4-related disease (IgG4-RD) in our cohort, and to investigate the characteristics, prognosis, and risk factors in the patients failed of remission induction. We prospectively enrolled 215 newly diagnosed patients with IgG4-RD, who were initially treated with glucocorticoid (GC) alone or in combination with immunosuppressive agents (IM), and had at least 6 months of follow up. The therapeutic goals of remission induction were defined as fulfilling each of the following after the 6-month remission induction stage: (1) ≥ 50% decline in the IgG4-RD responder index (RI); (2) GC tapered to maintenance dose; and (3) no relapse during GC tapering. The patients not achieving the therapeutic goals were considered to have failed of remission induction. There were 26 patients in our cohort who failed of remission induction, including 16 (20.8%) on GC monotherapy, and 10 (7.2%) on combination therapy comprising GC and IM. The lacrimal gland and lung were most common sites of remission induction failure. Among the patients who relapsed during remission induction stage, 52.9% had secondary relapse during follow-up. Eosinophilia, higher baseline RI, more than five organs involved and dacryoadenitis were risk factors for remission induction failure with GC monotherapy, and the incidence of remission induction failure was 71.4% in the patients with more than three risk factors. After 6-month treatment, the patients who failed of remission induction had significantly higher erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and IgG4. In our cohort, 20.8% of patients failed of remission induction with GC monotherapy, while 7.2% of patients failed of remission induction with combination therapy comprising GC and IM.

1 February 2019 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
MWMu Wang
Mu Wang
PZPanpan Zhang
Panpan Zhang
WLWei Lin
Wei Lin
YFYunyun Fei
Yunyun Fei
HCHua Chen
Hua Chen
WZWen Zhang
Wen Zhang
This study aimed to compare the differences and similarities in the clinical manifestations and treatment efficacy of IgG4-related disease (IgG4-RD) in patients with and without dacryoadenitis and sialoadenitis (DS). A total of 121 untreated IgG4-RD patients in Peking Union Medical College Hospital were enrolled in this study. The patients were divided into three groups: DS-predominant (group A), non-DS (group B), and DS with other internal organs affected (group C). The patients were followed up for at least 15 months. Baseline and follow-up data were collected. The disease activity was evaluated according to the IgG4-RD responder index. The mean ± SD age at disease onset was 53.2 ± 14.1 years, and 71.9% of the patients were male. The prevalence of allergies was higher in groups A (21, 61.8%) and C (32, 69.6%) than group B (14, 34.1%). More patients with DS (17, 50.0%, and 17, 37.0%) had sinonasal lesions than those without DS (5, 12.2%). Moreover, an increased number of eosinophils were more common in patients with DS than in those without, as were increased serum IgG, IgG4, and IgE levels. More patients in group B and group C (28, 68.3%, and 31, 67.4%) received a combination therapy of corticosteroid and immunosuppressant. During the 15-month follow-up, 28 (23.1%) patients had disease relapse. Results demonstrated that IgG4-RD patients with DS had distinctive clinical features compared with non-DS. Allergy and sinonasal involvement were more common in patients with DS. Patients with DS showed higher serum IgG4 levels than those without DS.

20 June 2023 in Heliyon
Verified
Journal Article
Open access
YLYanchen Li
Yanchen Li
KWKuo Wan
Kuo Wan
MWMu Wang
Mu Wang
GCGePing Cui
GePing Cui
BCBo Chen
Bo Chen
TZTao Zhang
Tao Zhang
Calcifying Epithelial Odontogenic Tumor (CEOT), also known as Pindborg tumor, is a rare odontogenic benign tumor. It was first reported by Thoma and Goldman in 1946 and defined as an independent tumor by Pindborg in 1957. Herein, we reported a CEOT case involving most of the mandible after I-125 implantation in a 53-year-old man. We cooperated with governmental and hospital departments to resect the tumors, reconstruct the mandible with a fibular flap graft, and properly dispose of the radioactive particles.

23 March 2025 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
MWMu Wang
Mu Wang
WHWeihua Han
Weihua Han
GKGe Kong
Ge Kong
SZShangzhu Zhang
Shangzhu Zhang
WZWen Zhang
Wen Zhang

27 March 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
YLYAO LI
YAO LI
MWMu Wang
Mu Wang
SQSiqi Qiu
Siqi Qiu
JCJinyan Chen
Jinyan Chen
FWFeng Wang
Feng Wang
This review aims to assess the clinical performance and application results of oral wearable devices in in vivo trials. Following a systematic search of PubMed, Cochrane, Embase, and Scopus databases up to 15 October 2025, and strict screening in accordance with PRISMA 2020 guidelines, 13 in vivo human trials were finally included for analysis. These were analyzed across four clinical functions: diagnosis, treatment, monitoring, and prevention. These devices have evolved from bulky prototypes into miniaturized, wireless systems with diverse diagnostic and therapeutic functions. Their applications now extend beyond common conditions like caries and bruxism to postoperative recovery and pediatric dental anxiety intervention. The findings show that some devices already offer practical value for clinical screening and auxiliary diagnosis. They demonstrate significant potential in early disease detection and medical cost control. However, development still faces many challenges. Technical issues include limited battery life, insufficient mechanical durability, and wireless transmission constraints within the oral environment. Furthermore, clinical evidence levels remain low, indications are narrow, and dedicated ethical and regulatory frameworks are lacking. Inconsistent regulatory standards, production costs, and clinician adoption hurdles slow its commercial development. In the future, the integration of AI, breakthroughs in energy harvesting, and the creation of digital health platforms will be key to overcoming technical bottlenecks.

9 June 2025 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
JCJingXuan Chang
JingXuan Chang
MWMu Wang
Mu Wang
JLJi Li
Ji Li